Hugh O'Dowd - 23 Mar 2022 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Reporting relationship: Chief Executive Officer
Issuer ticker: TXMD
Reported as of: 23 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Mar 2022, 07:00:20 UTC
Prior SEC filing: 31 Aug 2021
Next SEC filing: 31 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Hugh O'Dowd

Key filing fact

Hugh O'Dowd filed Form 4 for TherapeuticsMD, Inc. (TXMD) on 28 Mar 2022.

Key facts

This page summarizes Hugh O'Dowd's Form 4 filing for TherapeuticsMD, Inc. (TXMD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Mar 2022, 07:00.

Change

Previous filing in this sequence was filed on 31 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TXMD transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +2,125,000
Change %
Price: $0.000000
Shares after: 2,125,000
Date: 23 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,125,000
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025.